Journal
ALZHEIMERS & DEMENTIA
Volume 17, Issue 1, Pages 103-111Publisher
WILEY
DOI: 10.1002/alz.12179
Keywords
Alzheimer's disease; biomarkers; early detection; eye; neurodegeneration; retina; retinal imaging
Categories
Funding
- Alzheimer's Association
- P.J. Snyder: the Morton Plant Mease Health Care Foundation, Clearwater, FL., USA
- NIH [P41EB-015903]
- Finker Frenkel Legacy Foundation
- Alzheimer's Association [AARGD17-531255]
- NIH/NIA [R01 AG055865, R01 AG056478]
- Alzheimer's Research Program
- Pratt Foundation
- Joan Margaret Ponting Charitable Trust & Hecht Charitable Trust
- National Foundation for Medical Research and Innovation
- Alzheimer's Drug Discovery Foundation
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- Canadian Institutes of Health Research, Canada (CIHR)
Ask authors/readers for more resources
Research on retinal imaging as potential biomarkers for Alzheimer's disease and other neurodegenerative diseases has significantly increased over the past 20 years. Discussions have focused on the different modalities of retinal imaging, their strengths and weaknesses, and the importance of defining the context of use to guide the development of retinal biomarkers.
In the last 20 years, research focused on developing retinal imaging as a source of potential biomarkers for Alzheimer's disease and other neurodegenerative diseases, has increased significantly. The Alzheimer's Association and the Alzheimer's & Dementia: Diagnosis, Assessment, Disease Monitoring editorial team (companion journal to Alzheimer's & Dementia) convened an interdisciplinary discussion in 2019 to identify a path to expedite the development of retinal biomarkers capable of identifying biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer's and other brain diseases, including a discussion of future directions for this area of study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available